The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor.

J Pediatr Gastroenterol Nutr · 2026 · PMC12780474 · PMID 41181888

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Nevertheless, the present cohort of pwCF with heterogeneous ETI therapy status reveals highly significant and clinically meaningful differences in AS of pwCF with and without treatment with the highly effective CFTR modulator.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.